Drug Trial Radar · NCT00522379
Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch
Last checked: Nov 20, 2026Latest source record: Oct 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
514
Actual
Start
Jul 2007
Primary completion
Jul 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Aug 29, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.
Conditions
- Parkinson's Disease
Interventions
RotigotineDrug
2 mg/24 hr (one 10 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
RotigotineDrug
4 mg/24 hr (one 20 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
PlaceboOther
Placebo transdermal patch applied daily
RotigotineDrug
6 mg/24 hr (one 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
RotigotineDrug
8 mg/24 hr (two 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Change in the Absolute Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily DiaryTime frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
Locations
77 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Tuscaloosa, Alabama
Site not named
Gilbert, Arizona
Site not named
Peoria, Arizona
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Little Rock, Arkansas
Site not named
Fountain Valley, California
Site not named
Fresno, California
Site not named
Irvine, California
Site not named
La Jolla, California
Site not named
Loma Linda, California
Site not named
Oxnard, California
Site not named
Aurora, Colorado
Site not named
New Haven, Connecticut
Site not named
Boca Raton, Florida
Site not named
Bradenton, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Naples, Florida
Site not named
Ocala, Florida
Site not named
Ormond Beach, Florida
Site not named
Pompano Beach, Florida
Site not named
St. Petersburg, Florida
Site not named
Sunrise, Florida
Site not named
Atlanta, Georgia
Site not named
Decatur, Georgia
Site not named
Macon, Georgia
Site not named
Suwanee, Georgia
Site not named
Chicago, Illinois
Site not named
Anderson, Indiana
Site not named
Des Moines, Iowa
Site not named
Kansas City, Kansas
Site not named
Louisville, Kentucky
Site not named
Southfield, Michigan
Site not named
Golden Valley, Minnesota
Site not named
St Louis, Missouri
Site not named
Missoula, Montana
Site not named
Omaha, Nebraska
Site not named
Las Vegas, Nevada
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.